Sarah E Daugherty

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi No evidence for anticipation in lymphoproliferative tumors in population-based samples
    Sarah E Daugherty
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, EPS Room 511, 6120 Executive Boulevard, Bethesda, MD 20892, USA
    Cancer Epidemiol Biomarkers Prev 14:1245-50. 2005
  2. ncbi RNASEL Arg462Gln polymorphism and prostate cancer in PLCO
    Sarah E Daugherty
    Department of Health and Human Services, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
    Prostate 67:849-54. 2007
  3. ncbi Polymorphic variants in alpha-methylacyl-CoA racemase and prostate cancer
    Sarah E Daugherty
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland, USA
    Prostate 67:1487-97. 2007
  4. ncbi Variants in the alpha-Methylacyl-CoA racemase gene and the association with advanced distal colorectal adenoma
    Sarah E Daugherty
    Divison of Cancer Epidemiology and Genetics, Department of Health and Human Services, National Cancer Institute, 6120 Executive Boulevard, EPS Rm 8113, Bethesda, MD 20892, USA
    Cancer Epidemiol Biomarkers Prev 16:1536-42. 2007
  5. ncbi Nonsteroidal antiinflammatory drugs and bladder cancer: a pooled analysis
    Sarah E Daugherty
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health DHHS, 6120 Executive Boulevard, Rockville, MD 20852, USA
    Am J Epidemiol 173:721-30. 2011
  6. ncbi Nonsteroidal anti-inflammatory drugs and glioma in the NIH-AARP Diet and Health Study cohort
    Sarah E Daugherty
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Department of Health and Human Services, Bethesda, Maryland, USA
    Cancer Prev Res (Phila) 4:2027-34. 2011
  7. ncbi Genetic polymorphisms of interleukin-1B (IL-1B), IL-6, IL-8, and IL-10 and risk of prostate cancer
    Dominique S Michaud
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland 20892, USA
    Cancer Res 66:4525-30. 2006

Detail Information

Publications7

  1. ncbi No evidence for anticipation in lymphoproliferative tumors in population-based samples
    Sarah E Daugherty
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, EPS Room 511, 6120 Executive Boulevard, Bethesda, MD 20892, USA
    Cancer Epidemiol Biomarkers Prev 14:1245-50. 2005
    ..This is the first study to consider the changes of incidence over time as a source of bias when evaluating anticipation in lymphoproliferative cancers...
  2. ncbi RNASEL Arg462Gln polymorphism and prostate cancer in PLCO
    Sarah E Daugherty
    Department of Health and Human Services, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
    Prostate 67:849-54. 2007
    ..The relationship of this variant to sporadic prostate cancer remains uncertain...
  3. ncbi Polymorphic variants in alpha-methylacyl-CoA racemase and prostate cancer
    Sarah E Daugherty
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland, USA
    Prostate 67:1487-97. 2007
    ..Significant differences in AMACR allele frequencies have been reported for hereditary prostate cancer (HPC), but the relevance of AMACR in the context of its substrates have not been studied...
  4. ncbi Variants in the alpha-Methylacyl-CoA racemase gene and the association with advanced distal colorectal adenoma
    Sarah E Daugherty
    Divison of Cancer Epidemiology and Genetics, Department of Health and Human Services, National Cancer Institute, 6120 Executive Boulevard, EPS Rm 8113, Bethesda, MD 20892, USA
    Cancer Epidemiol Biomarkers Prev 16:1536-42. 2007
    ..AMACR gene variants have been associated with hereditary prostate cancer, but no studies have evaluated their etiologic role in colorectal carcinogenesis...
  5. ncbi Nonsteroidal antiinflammatory drugs and bladder cancer: a pooled analysis
    Sarah E Daugherty
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health DHHS, 6120 Executive Boulevard, Rockville, MD 20852, USA
    Am J Epidemiol 173:721-30. 2011
    ..04, 95% CI: 0.94, 1.15). Results suggest that nonaspirin NSAIDs, but not aspirin, are associated with a reduction in risk of bladder cancer, particularly for nonsmokers...
  6. ncbi Nonsteroidal anti-inflammatory drugs and glioma in the NIH-AARP Diet and Health Study cohort
    Sarah E Daugherty
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Department of Health and Human Services, Bethesda, Maryland, USA
    Cancer Prev Res (Phila) 4:2027-34. 2011
    ..90; 95% CI, 0.65-1.25 and HR for glioblastoma = 0.83; 95% CI, 0.56-1.20) as compared with no use. Our findings from this large prospective study do not support an inverse association between NSAIDs and risk of all glioma or glioblastoma...
  7. ncbi Genetic polymorphisms of interleukin-1B (IL-1B), IL-6, IL-8, and IL-10 and risk of prostate cancer
    Dominique S Michaud
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland 20892, USA
    Cancer Res 66:4525-30. 2006
    ..At least seven common polymorphisms in genes of inflammatory cytokines IL-1B, IL-6, IL-8, and IL-10 do not seem to play a role in the risk of prostate cancer...